GENERAL COMMENTS
Several studies have already demonstrated that baseline plasma fibrinogen levels could predict CVE in general individuals and nondiabetics. However, the present study first evaluated the predictive value of fibrinogen for cardiovascular events especially in Chinese patients with T2DM along with stable CAD, containing a large sample size and using professional study design as well as appropriate methods. I appreciate your study and honesty for study limitations. Nonetheless, I've got several questions about it.
Major points: Although your study contains a large sample size of 1466 patients, only 96 patients developed CVE, which is relatively small to investigate the predictive value of fibrinogen. Since you've defined it as one of the study limitations, could you further explain how the study size was arrived at in your study design?
As shown by KM curves and COX regression analysis, patients in the high level group are at highest risk of CVE compared with both low and middle group. However, the difference between low and middle group seemed not significant. Could you establish a cut-off value of fibrinogen best predict CVE in these patients?
All of your analyses and results focused on T2DM patients with CAD and the reason of such choice is clearly clarified in your introduction and discussion. Nevertheless, I'm curious if the predictive value of fibrinogen for CVE still exists in angiographic-proven CAD patients but without T2DM.
Minor points: First of all, according to your inclusion and exclusion criteria (page 4), were patients with old myocardial infarction, stroke or atrial fibrillation included in your study? Could these medical histories influence fibrinogens levels? Also did any comorbidity such as hypertension affect the predictive value of fibrinogen for CVE in patients with T2DM?
As shown in table 1, patients in both CVE and no CVE group use similar medication. Moreover, although I can tell the association between fibrinogen and hyperlipemia as well as blood glucose, I couldn't find the relationship between fibrinogen and medication. Could medication affect fibrinogen levels analyzed in your study as well as other studies? Moreover, why not adjust for medication such as statin use in your COX regression models?
Fibrinogen in men is shown to be much lower than that in women in table 2, also you've indicated that fibrinogen was a significant and independent predictor of coronary heart disease in men in another cohort (page 10, paragraph 2, line 4). Is the predictive value of fibrinogen significantly different between men and women in your cohort?
In References in the introduction need to be better organized. In fact several other papers already reported by the authors (i.e. 25, 26 ecc) have to be mentioned also in the introduction along with references 15-17.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Question 1: Although your study contains a large sample size of 1466 patients, only 96 patients developed CVE, which is relatively small to investigate the predictive value of fibrinogen. Since you've defined it as one of the study limitations, could you further explain how the study size was arrived at in your study design? Response: Thank you for your scientific comment. In fact, our study is a prospective registry study for CAD patients (Would you kindly find our published papers, e.g. Medicine (Baltimore). 2015;94:e2426; Ann Med. 2016;48:83-8; J Clin Lipidol. 2015;9:794-800)? The aim of this study is to investigate the role of fibrinogen in CVE in Chinese patients with CAD and T2DM. In the present study, we defined the follow-up outcomes (Page 5, Paragraph 4). Hence, this study is just one part of our prospective registry study for CAD patients, and the follow-up is still continued.
Question 2: As shown by KM curves and COX regression analysis, patients in the high level group are at highest risk of CVE compared with both low and middle group. However, the difference between low and middle group seemed not significant. Could you establish a cut-off value of fibrinogen best predict CVE in these patients? Response: Thank you for your advice. In the present study, we found that 3.515(g/L) is a cut-off value of fibrinogen to predict CVEs in Chinese diabetics with coronary artery disease, which is consistent with previous study [1] .We have added this information into the section of discussion in the revised manuscript (Please see page 11, Paragraph 2, Line 20-21 Question 4: First of all, according to your inclusion and exclusion criteria (page 4), were patientswith old myocardial infarction, stroke or atrial fibrillationincluded in your study? Could these medical histories influence fibrinogens levels? Also did any comorbidity such as hypertension affect the predictive value of fibrinogen for CVE in patients with T2DM? Response: Thank you very much for your scientific question. In the present study, patients with previous PCI, CABG, stroke or atrial fibrillation were also included due to stable status of the disease. Besides, there is no difference between the CVE group and non-CVE group (See Table 1 ). Moreover, there is no difference in the percentage of the common medicine use or hypertension status between the CVE group and non-CVE group (Table 1) . Similarly, a significant difference was not found in usage rate of medicines or or hypertension status across fibrinogen level tertiles (Table 2 ).
Question 5: As shown in table 1, patients in both CVE and no CVE group use similar medication. Moreover, although I can tell the association between fibrinogen and hyperlipemia as well as blood glucose, I couldn't find the relationship between fibrinogen and medication. Could medication affect fibrinogen levels analyzed in your study as well as other studies? Moreover, why not adjust for medication such as statin use in your COX regression models? Response: Thank you very much for your good question. Indeed, it is difficult to find out whether medicines can affect the predictive value of fibrinogen for CVE in this study, because we just evaluated the predictive value just according to one-time levels of fibrinogen. However, no difference in medicine use was found in various levels of fibrinogen when the baseline characters were collected (Table 2) . Moreover, there was no significant difference in medicine use between the patients with or without CVE (Table 1) . Since the subjects we enrolled were patients with CAD and T2DM, statin use was very common and there was no difference in statin use across fibrinogen tertiles (Table 2) . Meanwhile, we found that after adjustment for statin use, fibrinogen remains associated with CVE in our cohort. In a word, our results are similar to previous studies [1] [2] [3] [4] . Question 6: Fibrinogen in men is shown to be much lower than that in women in table 2, also you've indicated that fibrinogen was a significant and independent predictor of coronary heart disease in men in another cohort (page 10, paragraph 2, line 4). Is the predictive value of fibrinogen significantly different between men and women in your cohort? Response: Thank you very much for your excellent question. Indeed, our results showed that fibrinogen level was higher in women than that in men, which is consistent with previous studies [1] [2] [3] .
Although fibrinogen level has been demonstrated to be associated with CVE in general population after adjustment for sex, few studies reported whether or not the predictive value of fibrinogen is significantly different between men and women. Soedamah-Muthu et al. reported that fibrinogen was a significant and independent predictor of coronary heart disease in menbut not in women [4], whereas, Stecet al. reported that fibrinogen level was a predictor of cardiovascular diseases in both men and women [5] . Actually, we wonder whether there is a similar result in our cohort. Unluckily, we did not evaluate if there was a significant difference about the relationship between fibrinogen and CVE in men and women because of fewer events. Thus, further study is required. In table 2 , LDL-C levels are significantly different among these three groups divided by fibrinogen tertiles, which means patients with higher fibrinogen level have much higher LDL-C level (low: 2.28±0.89, middle: 2.52±0.94, high: 2.60±1.01, p<0.001). But in your COX regression analysis, none of these 5 models contains LDL-C. Why don't you adjust for LDL-C level but choose HDL-C and triglycerides instead? Response: Thank you very much for pointing out the mistake. In fact, we had adjusted LDL-C but overlooked it because of our carelessness. We have corrected it.
Question 8: Diabetes mellitus was defined as a fasting plasma glucose ≥126 mg/dL (7.0mmol/L) in multiple determinations, and/or the current use of medication for diabetes in your study (page 5, paragraph 3, Line 2-3), also the severity of DM and disease progression could affect the occurrence rate of CVE. In table 2, fibrinogen levels seem to be positively correlated to serum glucose. Could it be influenced by medication for diabetes? Response: Thank you very much for your sound question. We have added this information to Table 1 and Table 2 . In Table 1 there was no difference in anti-diabetic drugs use between the patients who developed CVE or not. Similarly, a significant difference in anti-diabetic medicine use was not found across the tertiles of fibrinogen levels (Table 2) . Moreover, we found that anti-diabetic drugs did not affect the relationship between fibrinogen and CVE in Cox model (data not shown).
Reviewer: 2 Question 2: Please report number of subjects for each fibrinogen levels low, medium and high. Why the authors have not used fibrinogen tertiles? Response: Thank you for your suggestion. We have reported the number of subjects for each fibrinogen levels low, medium and high in Table 2 . Actually, we trisected fibrinogen levels into (≤2.91 g/L), (2.91-3.51 g/L) and (≥3.51 g/L) (See page 6, paragraph 2, line 2). "Low", "Middle" and "High" levels of fibrinogen are just named artificially according to fibrinogen tertiles. Question 4: The data showing an increased number of female among patients with middle and high fibrinogen levels are interesting. Have the authors tested for a possible interaction between fibrinogen and sex? Response: Thank you for your important question. Indeed, our results showed that the fibrinogen level was higher in women than that in men, which is in agreement with previous studies [1] [2] [3] [4] . After testing, we have not found a possible interaction between fibrinogen and sex in our cohort. Despite all this, we cannot determine whether or not a possible interaction between fibrinogen and sex exists due to our relatively small sample, so further study is needed.
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